CME
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
May 09, 2024
Host: Javier Cortes, MD, PhD
Guest: Komal Jhaveri, MD, FACP
The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly impr
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!